Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

Summary Aims To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. Methods In a 12‐week, double‐blind trial, subjects with self‐reported OAB symptoms for ≥ 6 months, mean of ≥ 8 m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical practice (Esher) 2014-09, Vol.68 (9), p.1065-1073
Hauptverfasser: Kaplan, S. A., Cardozo, L., Herschorn, S., Grenabo, L., Carlsson, M., Arumi, D., Crook, T. J., Whelan, L., Scholfield, D., Ntanios, F.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Benzhydryl Compounds - administration & dosage
Benzhydryl Compounds - adverse effects
Benzhydryl Compounds - therapeutic use
Bladder
Double-Blind Method
Drug therapy
Female
Humans
Male
Middle Aged
Muscarinic Antagonists - administration & dosage
Muscarinic Antagonists - adverse effects
Muscarinic Antagonists - therapeutic use
Quality of Life
Surveys and Questionnaires
Tolterodine Tartrate - administration & dosage
Tolterodine Tartrate - therapeutic use
Treatment Outcome
Urinary Bladder, Overactive - drug therapy
Urinary incontinence
Urology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Aims To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. Methods In a 12‐week, double‐blind trial, subjects with self‐reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturitions and ≥ 2 to
ISSN:1368-5031
1742-1241
DOI:10.1111/ijcp.12464